US 12,441,807 B2
Bispecific antibodies against CEACAM5 and CD3
Klaus Strein, Weinheim (DE); and Sara Majocchi, Grand Lancy (CH)
Assigned to LAMKAP BIO ALPHA AG, Pfaeffikon (CH)
Appl. No. 17/761,531
Filed by LamKap Bio Alpha AG, Pfaeffikon (CH)
PCT Filed Sep. 17, 2020, PCT No. PCT/IB2020/058690
§ 371(c)(1), (2) Date Mar. 17, 2022,
PCT Pub. No. WO2021/053587, PCT Pub. Date Mar. 25, 2021.
Claims priority of provisional application 62/902,150, filed on Sep. 18, 2019.
Claims priority of application No. 19198124 (EP), filed on Sep. 18, 2019.
Prior Publication US 2023/0136228 A1, May 4, 2023
Int. Cl. C07K 16/30 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/3007 (2013.01) [A61K 39/001129 (2018.08); A61K 39/001182 (2018.08); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/35 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01)] 11 Claims
 
1. A bispecific antibody comprising a first binding part, specifically binding to human CEACAM5, and a second binding part, specifically binding to human CD3ε, wherein:
a) the first binding part comprises a heavy chain variable region (VH), which comprises a CDRH1 of SEQ ID NO: 2, a CDRH2 of SEQ ID NO: 3 and a CDRH3 of SEQ ID NO: 4,
b) the first binding part comprises a light chain variable region (VL) comprising a CDRL set selected from the group consisting of
b1) a CDRL1 of SEQ ID NO: 32, CDRL2 of SEQ ID NO: 33, and CDRL3 of SEQ ID NO: 34,
b2) a CDRL1 of SEQ ID NO: 81, CDRL2 of SEQ ID NO: 82, and CDRL3 of SEQ ID NO: 83,
b3) a CDRL1 of SEQ ID NO: 84, CDRL2 of SEQ ID NO: 85, and CDRL3 of SEQ ID NO: 86,
b4) a CDRL1 of SEQ ID NO: 87, CDRL2 of SEQ ID NO: 88, and CDRL3 of SEQ ID NO: 89,
b5) a CDRL1 of SEQ ID NO: 90, CDRL2 of SEQ ID NO: 91, and CDRL3 of SEQ ID NO: 92,
b6) a CDRL1 of SEQ ID NO: 93, CDRL2 of SEQ ID NO: 94, and CDRL3 of SEQ ID NO: 95,
b7) a CDRL1 of SEQ ID NO: 96, CDRL2 of SEQ ID NO: 97, and CDRL3 of SEQ ID NO: 98,
b8) a CDRL1 of SEQ ID NO: 99, CDRL2 of SEQ ID NO: 100, and CDRL3 of SEQ ID NO: 101,
b9) a CDRL1 of SEQ ID NO: 102, CDRL2 of SEQ ID NO: 103, and CDRL3 of SEQ ID NO: 104,
b10) a CDRL1 of SEQ ID NO: 105, CDRL2 of SEQ ID NO: 106, and CDRL3 of SEQ ID NO: 107,
b11) a CDRL1 of SEQ ID NO: 108, CDRL2 of SEQ ID NO: 109, and CDRL3 of SEQ ID NO: 110, and
b12) a CDRL1 of SEQ ID NO: 111, CDRL2 of SEQ ID NO: 112, and CDRL3 of SEQ ID NO: 113,
c) the second binding part comprises a VH comprising a CDRH1 of SEQ ID NO: 2, CDRH2 of SEQ ID NO: 3 and CDRH3 of SEQ ID NO: 4, and
d) the second binding part comprises a VL comprising a CDRL1 of SEQ ID NO: 18, CDRL2 of SEQ ID NO: 19, and CDRL3 of SEQ ID NO: 20.